Introduction
Methods
Search strategy
Parameter | Description |
---|---|
Participants | Healthy individuals |
Intervention | Prototypical non-caloric tastants at least once |
Comparison | Prototypical non-caloric tastants vs. placebo |
Outcomes | Energy intake, GI symptoms and perceptions, and mechanisms of effect |
Setting | Randomized controlled trials with a parallel or crossover design |
Research question | What is the effect of post-oral delivery of non-caloric tastants on energy intake in healthy volunteers? Secondary: what is the effect of post-oral delivery of non-caloric tastants on GI symptoms and perceptions and what is the effect of post-oral delivery of non-caloric tastants on mechanisms of action in healthy volunteers |
Selection criteria
Outcome measures
Data extraction
Quality assessment
Statistical analysis
Data reporting
Results
Systematic approach to paper selection
Quality assessment
Study characteristics
Study population
Tastants used
Tastant | Ligand receptors |
---|---|
Aspartame | TAS1R2/TAS1R3 heterodimer |
Saccharin | TAS1R2/TAS1R3 heterodimer, TAS2R43, TAS2R44 |
Sucralose | TAS1R2/TAS1R3 heterodimer, TAS2R1, TAS2R4, TAS2R5, TAS2R7, TAS2R8, TAS2R10, TAS2R39, TAS2R41, TAS2R41, TAS2R46 |
Ace-K | TAS1R2/TAS1R3 heterodimer, TAS2R43, TAS2R44 |
Reb-A | TAS1R2/TAS1R3 heterodimer, TAS2R4, TAS2R14 |
Xylitol | TAS1R2/TAS1R3 heterodimer |
Erythritol | TAS1R2/TAS1R3 heterodimer |
Naringin | N/A |
Quinine | TAS2R4, TAS2R7, TAS2R10, TAS2R14, TAS2R39, TAS2R40, TAS2R43, TAS2R44, TAS2R46 |
QHCl | TAS2R4, TAS2R7, TAS2R10, TAS2R14, TAS2R39, TAS2R40, TAS2R43, TAS2R44, TAS2R46 |
DB | TAS2R4, TAS2R8, TAS2R10, TAS2R13, TAS2R39, TAS2R43, TAS2R46, TAS2R47 |
Bitter secoiridoids (Gentiana lutea extract, contains amarogentin) | TAS2R1, TAS2R4, TAS2R39, TAS2R43, TAS2R46, TAS2R47, TAS2R50 |
Raisin flavor | N/A |
Sucrose octaacetate | TAS2R46 |
Quassia extract | TAS2R4, TAS2R10, TAS2R14, TAS2R46, TAS2R47 |
Amarasate extract | N/A |
MSG | TAS1R1/TAS1R3 heterodimer |
Sweet tastants
Bitter tastants
Umami tastants
Combination of tastants
Comparators
Energy intake
Taste | References | Subjects | Tastants and comparators used | Method of administration | Interval intervention to meal | Energy intake (Kcal) | Direction of effect |
---|---|---|---|---|---|---|---|
Sweet | Rogers et al. (1990) [40] UK | 12 subjects (6 men, 6 women, 18–26 y, BMI 20.8) | Aspartame capsule (234 mg) Comparator: Placebo capsule | Gastric capsule | 60 min | − 175 kcal | ↓ |
15 subjects (10 men, 5 women, 19-24 y, normal BMI | Aspartame capsule (235 mg) Aspartame capsule (470 mg) Comparator: Placebo capsule | Gastric capsule | 60 min | − 138 kcal for 235 mg aspartame − 150 kcal for 470 mg aspartame | ↓ | ||
Black et al. (1993) [44] Canada | 18 subjects (18 men, 19-25y, BMI 21–25) | Aspartame capsule (340 mg) Comparator: Water | Gastric capsule | 60 min | Slight non-significant increase in energy intake (numbers not shown) No effect on macronutrient composition | No effect | |
Van Avesaat et al. (2015) [42] The Netherlands | 15 subjects (6 men, 9 women, 22.4 y, BMI 22.4) | Reb-A (540 mg) Comparator: Tap water | Nasoduodenal catheter | 75 min | − 24 kcal (n.s.) | No effect | |
Bitter | Andreozzi et al. (2015) [27] Italy | 20 subjects (8 men, 12 women, 27 y, BMI 24) | QHCl capsule (18 mg) Comparator: Placebo capsule | Acid resistant capsules | 60 min | -82 kcal | ↓ |
Van Avesaat et al. (2015) [42] The Netherlands | 15 subjects (6 men, 9 women, 22.4 y, BMI 22.4) | QHCl (75 mg) Comparator: Tap water | Nasoduodenal catheter | 75 min | − 44 kcal (n.s.) | No effect | |
Mennella et al. (2016) [37] Italy | 20 subjects (11 men, 9 women, 25.3 y, BMI 22.1 | Microencapsulated bitter secoiridoids (100 mg) Comparator: coating only | Microencapsulation to mask oral tasting. Exact location of effect in GI tract unknown | 180 min (lunch) 24 h energy intake | Lunch:—88 kcal (n.s.) Post-lunch: − 252 kcal 24 h energy intake: − 340 kcal | ↓ | |
Peters et al. (2016) [39] The Netherlands | 57 subjects (all women, 40.5 y, BMI 26.5) | Bitter mixture containing: Raisin flavor (22.0 mg) Sucrose Octa Acetate (0.88 mg) Quassia extract (0.088 mg) Comparator: placebo capsule | Intragastric capsule, 2 times daily for 14 days | 60 min (breakfast) 300 min (lunch) 60 min (dinner) All day energy intake | Day 0 vs. day 14: Meals only: − 109 kcal (n.s.) Meals + snack: -86 kcal (n.s.) Breakfast: − 30 kcal (n.s.) Lunch: − 61 kcal (n.s.) Dinner: − 1 kcal (n.s.) Snacks: + 41 kcal (n.s.) | No effect | |
Deloose et al. (2017) [32] Belgium | 20 subjects (all women, 23 y, BMI 22) | DB (0.447 mg/Kg body weight) Comparator: Tap water | Nasogastric catheter | 40 min | − 76 kcal (n.s.) | No effect | |
Bitarafan et al. (2019) [30] Australia | 14 subjects (14 men, 25 y, BMI 22.5) | QHCl (37.5 mg, Q37.5)) QHCl (75 mg, Q75)) QHCl (225 mg, Q225)) Comparator: Saline | Nasoduodenal catheter | 60 min | Q37.5:—31Kcal (n.s.), Q75: − 59 kcal (n.s.), Q225: − 11 kcal vs. Control (n.s.) | No effect | |
Iven et al. (2019) [33] Belgium | 16 subjects (16 women, 24.5 y, BMI 21.9) | QHCl (3.6 mg/Kg body weigh) Comparator: Milli-Q water | Nasogastric catheter | 40 min | − 67.6 kcal | ↓ | |
Bitarafan et al. (2020) [29] Australia | 12 subjects (12 men, 26 y, BMI 23.1) | QHCl (275 mg, Q275) QHCl (600 mg, Q600) Comparator: Saline | Nasogastric catheter | 30 min | Q275: + 26 kcal, Q600: − 53 kcal (n.s.) | No effect | |
Umami | Van Avesaat et al. (2015) [42] The Netherlands | 15 subjects (6 men, 9 women, 22.4 y, BMI 22.4) | MSG (2 g) Comparator: Tap water | Intraduodenal catheter | 75 min | + 5 kcal (n.s.) | No effect |
Combination | Van Avesaat et al. (2015) [42] The Netherlands | 15 subjects (6 men, 9 women, 22.4 y, BMI 22.4) | Tastant mixture: Reb-A (540 mg) QHCl (75 mg) MSG (2 g) Comparator: Tap water | Nasoduodenal catheter | 75 min | − 64 kcal | ↓ |
Klaassen et al. (2019) [34] The Netherlands | 14 subjects (3 men, 11 women, 25.6 y, BMI 22.3) | Tastant mixture: Reb-A (540 mg) QHCl (75 mg) MSG (2 g) Comparator: Tap water | Naso-duodenal-ileal catheter | 75 min | Duodenal + 16.7 kcal (n.s.), Ileal + 28.1 kcal (n.s.), Combined duodenal and ileal + 31.5 kcal (n.s.) | No effect |
Sweet tastants
Bitter tastants
Umami tastants
Combination of tastants
GI symptoms and perceptions
Taste | References | Subjects | Tastants and comparators used | Method of administration | GI symptoms and perceptions | Direction of effect |
---|---|---|---|---|---|---|
Sweet | Rogers et al. (1990) [40] UK | 15 subjects (10 men, 5 women, 19-24 y, normal BMI | Aspartame capsule (235 mg) Aspartame capsule (470 mg) Comparator: Placebo capsule | Gastric capsule | Aspartame capsules reduced desire to eat and hunger scores Aspartame capsules tended to increase fullness compared with placebo (n.s.) | ↓ desire to eat/hunger No effects fullness |
Black et al. (1993) [44] Canada | 18 subjects (18 men, 19–25 y, BMI 21–25) | Aspartame capsule (340 mg) Comparator: Water | Gastric capsule | No effects of aspartame on appetite sensations | No effects | |
Little et al. (2009) [35] UK | 10 subjects | Saccharin (50 mg) Aspartame (200 mg) Comparator: Tap water | Nasogastric catheter | No effects of aspartame or saccharin on hunger or fullness | No effects | |
Steinert et al. (2011) [41] Switzerland | 12 subjects (6 men, 6 women, 23.3 y, BMI 23.0) | Aspartame (160 mg) Ace-K (200 mg) sucralose (62 mg) Comparator: Tap water | Nasogastric catheter | Artificial sweeteners reduced hunger, and increased satiety and fullness ratings to an intermediate amount between water and carbohydrate sugars (n.s.) | No effects | |
Van Avesaat et al. (2015) [42] The Netherlands | 15 subjects (6 men, 9 women, 22.4 y, BMI 22.4) | Reb-A (540 mg) Comparator: Tap water | Nasoduodenal catheter | Reb-A did not influence appetite sensations. Reb-A did not induce GI symptoms | No effects | |
Wölnerhanssen et al. (2016) [43] Switzerland | 20 subjects 10 lean subjects (5 men, 5 women, 26.6 y, BMI 21.7) 10 obese subjects (5 men, 5 women, 27.2 y, BMI 40.0) | Xylitol (50 g) Erythritol (75 g) Comparator: Tap water | Nasogastric catheter | Both sweeteners did not affect appetite sensations. Xylitol and erythritol led to bloating and diarrhea in 70% and 60% of subjects, respectively | No effects appetite sensations ↑Side effects | |
Meyer-Gerspach et al. (2018) [38] Belgium | 12 subjects (6 men, 6 women, 23 y, BMI 23) | Ace-K (220 mg) Comparator: Tap water | Nasogastric catheter | Hunger: Strong initial decrease in hunger after Ace-K with a faster return of hunger after first time point and slower return of hunger in last part of curve after Ace-K vs. Control Satiation: Strong initial increase in satiation after Ace-K vs. control with faster decrease after first time point and slower decrease in last part of curve after Ace-K vs. control No adverse events | ↓Hunger ↑Satiation No adverse events | |
Bitter | Little et al. (2009) [35] UK | 12 subjects | Naringin (290.27 mg) Quinine (32.2 mg) Comparator: Tap water | Nasogastric catheter | No effects of naringin or quinine on appetite sensations | No effects |
Andreozzi et al. (2015) [27] Italy | 20 subjects (8 men, 12 women, 27 y, BMI 24) | QHCl capsule (18 mg) Comparator: Placebo capsule | Acid resistant capsules | QHCl did not affect satiety or desire to eat scores vs. Control No adverse events | No effects No adverse events | |
Avau et al. (2015) [28] Belgium | 12 subjects (5 men, 30.6 y, BMI 23.8) | DB (0.447 mg/kg body weight) Comparator: Saline | Nasogastric catheter | DB made subjects feel satiated earlier and at lower volumes during constant nutrient infusion No adverse effects | ↑Satiation No adverse events | |
Van Avesaat et al. (2015) [42] The Netherlands | 15 subjects (6 men, 9 women, 22.4 y, BMI 22.4) | QHCl (75 mg) Comparator: Tap water | Nasoduodenal catheter | Quinine did not influence appetite sensations Quinine did not induce GI symptoms | No effects No GI symptoms | |
Mennella et al. (2016) [37] Italy | 20 subjects (11 men, 9 women, 25.3 y, BMI 22.1 | Bitter secoiridoids (100 mg) Comparator: Coating only | Microencapsulation to mask oral tasting. Exact location of effect in GI tract unknown | No effect of bitter encapsulate on fullness, satiety, hunger or desire to eat | No effects | |
Deloose et al. (2017) [32] Belgium | 20 subjects (10 men, 10 women, 27 y, BMI 24) | DB (0.447 mg /Kg body weight) Comparator: Tap water | Nasogastric catheter | Women: Switch from gastric to duodenal phase 3 origin was accompanied by lower percentage change of hunger scores after DB vs. Control Men: Percentage change in hunger scores during phase 3 contraction did not differ after DB vs. Control (n.s.) No adverse events after DB administration | ↓Hunger in women | |
12 subjects (all women, 31 y, BMI 22) | DB (0.447 mg /Kg body weight) Comparator: Tap water | Nasogastric catheter | No adverse events after DB administration | No adverse events | ||
13 subjects (all women, 28 y, BMI 23) | DB (0.447 mg /Kg body weight) Comparator: Tap water | Nasogastric catheter | Hunger scores after a standardized meal were lower after DB vs. Control. Satiety scores were higher after a standardized meal after DB No adverse events after DB administration | ↓Hunger ↑Satiety No adverse events | ||
20 subjects (all women, 23 y, BMI 22) | DB (0.447 mg /Kg body weight) Comparator: Tap water | Nasogastric catheter | No adverse events after DB administration | No adverse events | ||
Deloose et al. (2018) [31] Belgium | 10 subjects (10 women, 33 y, BMI 22) | QHCl (3.6 mg/kg body weight) Comparator: Milli-Q water | Nasogastric catheter | No adverse events | No adverse events | |
Bitarafan et al. (2019) [30] Australia | 14 subjects (14 men, 25 y, BMI 22.5) | QHCl (37.5 mg, Q37.5)) QHCl (75 mg, Q75)) QHCl (225 mg, Q225)) Comparator: Saline | Nasoduodenal catheter | No differences in VAS scores for hunger, desire to eat, prospective consumption, or fullness after Q37.5, Q75, or Q225 vs. Control No adverse events, no effects of Q37.5, Q75, or Q225 on nausea or bloating | No effects No GI symptoms No adverse events | |
Iven et al. (2019) [33] Belgium | 16 subjects (16 women, 24.5 y, BMI 21.9) | QHCl (3.6 mg/Kg body weigh) Comparator: Milli-Q water | Nasogastric catheter | Hunger scores increased after control and decreased after QHCl (n.s.) Prospective food consumption scores decreased after QHCl vs. Control Satiety scores increased after QHCl vs. Control Fullness scores increased after QHCl vs. control Minimal nausea scores reported (n.s.) | ↓Prospective food consumption ↑Satiety ↑Fullness No GI symptoms | |
Walker et al. (2019) [45] New Zealand | 30 subjects (30 men, 24y, BMI 23.1) | Amarasate extract (500 mg, HD) Amarasate extract (200 mg, LD) Comparator: Placebo capsule | Acid resistant capsule | From T = 90 onwards HD and LD show lower mean changes in hunger and fullness Lower mean changes in fullness for HD from t = 120 onwards, only t = 180 and t = 330 for LD No nausea. 3 participants in HD and 1 in LD had liquid loose bowel movements | ↓Hunger ↑Fullness No GI symptoms | |
Bitarafan et al. (2020) [29] Australia | 15 subjects (15 men, 26 y, BMI 23.2) | QHCl (275 mg, Q275) Quinine-HCl (600 mg, Q600) Comparator: Saline | Nasogastric catheter | No effects of Q275 or Q600 on hunger, desire to eat, prospective consumption, or fullness scores No effects of Q275 or Q600 on bloating or nausea vs. Control. No other adverse effects | No effects No GI symptoms No adverse events | |
12 subjects (12 men, 26 y, BMI 23.1) | QHCl (275 mg, Q275) QHCl (600 mg, Q600) Comparator: Saline | Nasogastric catheter | No effects of Q275 or Q600 on hunger, desire to eat, prospective consumption, or fullness scores No effects of Q275 or Q600 on bloating or nausea vs. Control. No other adverse effects | No effects No GI symptoms No adverse events | ||
Umami | Van Avesaat et al. (2015) [42] The Netherlands | 15 subjects (6 men, 9 women, 22.4 y, BMI 22.4) | MSG (2 g) Comparator: Tap water | Intraduodenal catheter | MSG decreased hunger and desire to eat but did not influence satiation or fullness MSG did not induce GI symptoms | ↓ Desire to eat/hunger No effects satiation/fullness No GI symptoms |
Combination | Van Avesaat et al. (2015) [42] The Netherlands | 15 subjects (6 men, 9 women, 22.4 y, BMI 22.4) | Tastant mixture: Reb-A (540 mg) QHCl (75 mg) MSG (2 g) Comparator: Tap water | Nasoduodenal catheter | The tastant mixture decreased hunger and desire to eat, but not satiation or fullness The tastant mixture did not induce GI symptoms | ↓ Desire to eat/hunger No effects satiation/fullness No GI symptoms |
Klaassen et al. (2019) [34] The Netherlands | 14 subjects (3 men, 11 women, 25.6 y, BMI 22.3) | Tastant mixture: Reb-A (540 mg) QHCl (75 mg) MSG (2 g) Comparator: Tap water | Naso-duodenal-ileal catheter | No effects of duodenal-, ileal- or combined duodenal and ileal delivery of non-caloric tastants on appetite sensations The tastant mixture did not induce GI symptoms | No effects No GI symptoms |
Sweet tastants
Bitter tastants
Umami tastants
Combination of tastants
Mechanisms of effect
Taste | References | Subjects | Tastants and comparators used | Method of administration | Mechanisms of effect | Direction of effect |
---|---|---|---|---|---|---|
Sweet | Little et al. (2009) [35] UK | 10 subjects | Saccharin (50 mg) Aspartame (200 mg) Comparator: Tap water | Nasogastric catheter | No effects of aspartame or saccharin on GE | No effects GE |
Ma et al. (2009) [36] Australia | 7 subjects (24 y, BMI 21.6) | Sucralose (80 mg) Sucralose (800 mg) Comparator: Saline | Nasogastric catheter | No effects of sucralose on GE, plasma glucose, plasma insulin, plasma GLP-1, or plasma GIP | No effects GE No effects GI peptides | |
Steinert et al. (2011) [41] Switzerland | 12 subjects (6 men, 6 women, 23.3 y, BMI 23.0) | Aspartame (160 mg) Ace-K (200 mg) Sucralose (62 mg) Comparator: Tap water | Nasogastric catheter | Sweeteners did not affect plasma GLP-1, PYY, ghrelin, glucose, insulin, or glucagon | No effects GI peptides | |
Van Avesaat et al. (2015) [42] The Netherlands | 15 subjects (6 men, 9 women, 22.4 y, BMI 22.4) | Reb-A (540 mg) Comparator: Tap water | Nasoduodenal catheter | Reb-A did not affect plasma CCK, GLP-1, or PYY | No effects GI peptides | |
Wölnerhanssen et al. (2016) [43] Switzerland | 20 subjects 10 lean subjects (5 men, 5 women, 26.6 y, BMI 21.7) 10 obese subjects (5 men, 5 women, 27.2 y, BMI 40.0) | Xylitol (50 g) Erythritol (75 g) Comparator: Tap water | Nasogastric catheter | Plasma CCK, plasma GLP-1, Plasma glucose increased after xylitol and erythritol vs. control Plasma insulin increased after xylitol, but not after erythritol vs. control Gastric emptying was slowed during the first 60 min after xylitol and erythritol vs. Control | ↓GE ↑plasma CCK, GLP-1, Glucose, insulin | |
Meyer-Gerspach et al. (2018) [38] Belgium | 12 subjects (6 men, 6 women, 23 y, BMI 23) | Ace-K (220 mg) Comparator: Tap water | Nasogastric catheter | No effect of Ace-K on plasma motilin, octanoylated ghrelin, active GLP-1, CCK, gastrin, and glucose GI motility did not differ between Ace-K and control A faster linear decrease in IGP from first post infusion time point, quicker return of IGP and quicker flattening of the curve during IGP recovery after Ace-K vs. Control with faster return to baseline in last part of the IGP curve after Ace-K vs. control | No effects GI motility ↓ IGP No effects GI peptides | |
Bitter | Little et al. (2009) [35] UK | 12 subjects | Naringin (290.27 mg) Quinine (32.2 mg) Comparator: Tap water | Nasogastric catheter | No effects of naringin or quinine on gastric emptying compared with water | No effects on GE |
Andreozzi et al. (2015) [27] Italy | 20 subjects (8 men, 12 women, 27 y, BMI 24) | QHCl capsule (18 mg) Comparator: Placebo capsule | Acid resistant capsules | CCK: Higher ΔT90 vs T0 and ΔT90 vs T60 after QHCl vs. Control GE (evaluated in 8 subjects): no differences in GE between QHCl (87 min) vs. Control (88 min) | No effect on GE ↑ CCK | |
Avau et al. (2015) [28] Belgium | 12 subjects (5 men, 30.6 y, BMI 23.8) | DB (0.447 mg/kg body weight) Comparator: Saline | Nasogastric catheter | Less drop in IGP after DB | ↑ IGP | |
Van Avesaat et al. (2015) [42] The Netherlands | 15 subjects (6 men, 9 women, 22.4 y, BMI 22.4) | QHCl (75 mg) Comparator: Tap water | Nasoduodenal catheter | Quinine did not affect plasma CCK, GLP-1, or PYY levels | No effects on GI peptides | |
Mennella et al. (2016) [37] Italy | 20 subjects (11 men, 9 women, 25.3 y, BMI 22.1 | Bitter secoiridoids (100 mg) Comparator: Coating only | Microencapsulation to mask oral tasting. Exact location of effect in GI tract unknown | Bitter encapsulate decreased plasma GLP-1 at 30 min, but had no effect on blood glucose, plasma amylin, plasma ghrelin, plasma glucagon, plasma GIP, plasma insulin, plasma leptin, plasma PP, or plasma PYY levels vs. Control | ↑ GLP-1 at 30 min No effects on other GI peptides | |
Deloose et al. (2017) [32] Belgium | 20 subjects (10 men, 10 women, 27 y, BMI 24) | DB (0.447 mg/Kg body weight) Comparator: Tap water | Nasogastric catheter | Women: DB reduced number of gastric phase 3 contractions from 67% (control) to 33% (DB) in women Interval between IG administration and occurrence of phase 3 did not differ between control (76 min) and DB (93 min) in women (n.s.) Men: No difference in origin of phase 3 contractions between control (57% gastric) and DB (40% gastric) in men (n.s.) Interval between IG administration and occurrence of phase 3 did not differ between control (76 min) and DB (111 min) in men (n.s.) | ↓ Gastric phase 3 contractions in women | |
12 subjects (all women, 31 y, BMI 22) | DB (0.447 mg/Kg body weight) Comparator: Tap water | Nasogastric catheter | Plasma motilin was lower after DB vs. Control. No differences between plasma total ghrelin or octanoylated ghrelin after DB vs. Control | ↓Plasma motilin No effect ghrelin | ||
13 subjects (all women, 28 y, BMI 23) | DB (0.447 mg/Kg body weight) Comparator: Tap water | Nasogastric catheter | GE (measured in 6 subjects) did not differ between control and DB (both 109 min | No effects on GE | ||
Deloose et al. (2018) [31] Belgium | 10 subjects (10 women, 33 y, BMI 22) | QHCl (0.447 mg/kg body weight) Comparator: Milli-Q water | Nasogastric catheter | Plasma motilin and plasma ghrelin levels decreased after QHCl. No difference in plasma octanoylated ghrelin levels Time* treatment effect for antral motility. No main effect of treatment No effects of QHCl on duodenal motility | ↓Antral motility ↓ plasma motilin and ghrelin | |
Bitarafan et al. (2019) [30] Australia | 14 subjects (14 men, 25 y, BMI 22.5) | QHCl (37.5 mg, Q37.5)) QHCl (75 mg, Q75)) QHCl (225 mg, Q225)) Comparator: Saline | Nasoduodenal catheter | No effects of Q37.5, Q75, and Q225 on plasma CCK or blood glucose vs. Control No effect of Q37.5, Q75, or Q225 on antral pressure waves, basal pyloric pressure, isolated pyloric pressure waves, and duodenal pressure waves vs. Control | No effects on GI motility No effects on GI peptides | |
Iven et al. (2019) [33] Belgium | 16 subjects (16 women, 24.5 y, BMI 21.9) | QHCl (3.6 mg/Kg body weigh) Comparator: Milli-Q water | Nasogastric catheter | Decreases in total ghrelin, octanoylated ghrelin, and motilin after QHCl vs. control Brain activity in homeostatic and hedonic regions: Increased activity after QHCl vs. Control in anterior insula, ACC, amygdala, putamen, nucleus accumbens, pallidum, caudate head and caudate body, medial and lateral OFC, hypothalamus and midbrain Decreased activity in brainstem/medulla | ↓ plasma ghrelin and motilin ↑Activity in homeostatic and hedonic brain regions ↓ activity in brainstem/medulla | |
Bitarafan et al. (2020) [29] Australia | 15 subjects (15 men, 26 y, BMI 23.2) | QHCl (275 mg, Q275) QHCl (600 mg, Q600) Comparator: Saline | Nasogastric catheter | Plasma insulin was increased 30 min after Q275 and Q600 vs. Control No effects of Q275 or Q600 on plasma glucose, plasma glucagon, or plasma GLP-1 After mixed nutrient drink: Q275 and Q600 lowered glucose Q275 and Q600 increased plasma insulin No difference in glucagon response after nutrient drink Q275 increased plasma GLP-1, Q600 did not No effects of Q275 or Q600 on gastric emptying | No effects on GE ↑ plasma insulin after intervention alone ↓ glucose after nutrient drink ↑ plasma insulin after nutrient drink ↑ plasma GLP-1 after nutrient drink | |
Umami | Van Avesaat et al. (2015)[42] The Netherlands | 15 subjects (6 men, 9 women, 22.4 y, BMI 22.4) | MSG (2 g) Comparator: Tap water | Intraduodenal catheter | MSG did not affect plasma CCK, GLP-1, or PYY levels | No effects on GI peptides |
Combination | Van Avesaat et al. (2015) [42] The Netherlands | 15 subjects (6 men, 9 women, 22.4 y, BMI 22.4) | Tastant mixture: Reb-A (540 mg) QHCl (75 mg) MSG (2 g) Comparator: Tap water | Nasoduodenal catheter | The tastant mixture did not affect plasma CCK, GLP-1, or PYY levels | No effects on GI peptides |